In vitro activity of ceftazidime-avibactam against Gram-negative strains in patients with complicated urinary tract infection and complicated intra-abdominal infection in Colombia 2014-2018

ABSTRACT

Ceftazidime/avibactam (CAZ/AVI) has excellent in vitro activity against enterobacterales and Pseudomonas aeruginosa. The study aimed to analyze the in vitro antimicrobial activity of CAZ/AVI and other antibiotics against isolates of enterobacterales and P. aeruginosa from patients with complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI) in Colombian hospitals between 2014 and 2018, using the Antimicrobial Testing Leadership and Surveillance (ATLAS) database. Enterobacterales and P. aeruginosa samples were obtained from patients with cUTI and cIAI. Susceptibility was determined using The Clinical and Laboratory Standards Institute (CLSI) breakpoints. Meropenem-non-susceptible isolates were screened for extended-spectrum b-lactamase (ESBL) production. Isolates that were positive for ESBL activity were examined by Multiplex Polymerase Chain Reaction (Multiplex PCR) to detect genotypic resistance. A total of 565 Enterobacterales and 95 P. aeruginosa from patients with cUTI and 345 Enterobacterales and 65 P. aeruginosa from patients with cIAI were isolated. In vitro activity showed susceptibility to CAZ/AVI greater than 99% for Enterobacterales and in lower percentages for P. aeruginosa in cUTI (78.46%) and cIAI (83.33%). CAZ/AVI showed good in vitro activity against multidrug-resistant (MDR) Enterobacterales and P. aeruginosa in patients with cUTI and cIAI.

Keywords:
Ceftazidime/avibactam; Gram-negative bacteria; Urinary tract infection; Complicated intra-abdominal infection

Complicated Urinary tract infection (cUTI) and intra-abdominal infection (cIAI) are mainly caused by multidrug-resistant (MDR) Gram-negative bacteria. The treatment of cUTI and cIAI caused by MDR Gram-negative bacteria is a problem in medical practice because of the unavailability of molecules with activity against these microorganisms, or the serious adverse effects of current therapy.¹ For this reason, the combination of new molecules has been studied, such as ceftazidime/avibactam (CAZ/AVI).

Studies have shown that CAZ/AVI had excellent in vitro activity against carbapenem-resistant Enterobacterales (CRE),² Enterobacterales producing KPC-type carbapenemases and carbapenem-resistant Pseudomonas aeruginosa.³ Additionally, different publications have reported that CAZ/AVI showed high activity against ceftazidime-resistant Enterobacterales,⁴ and ESBL-producing E. coli and K. pneumoniae in patients with cUTI and cIAI.⁵ CAZ/AVI has also been found to have a good in vitro response against carbapenemase-producing Enterobacterales, specifically KPC (100% susceptibility) and OXA-48 (100% susceptibility); the in vitro activity is maintained even in those strains resistant to ceftazidime and meropenem.⁶

In Colombia, ceftazidime/avibactam(Zavicefta®) has had a registration certificate since 2019, and it is indicated for the treatment of cIAI, in combination with metronidazole, cUTI (including pyelonephritis), and hospital-acquired pneumonia (including ventilator-associated pneumonia) in adults, infants from 3 months onwards, children and adolescents.⁷ For this reason, it is important to conduct studies that evaluate in vitro activity of this molecule against Gram-negative strains in patients with cUTI and cIAI.

The study aimed to evaluate the in vitro antimicrobial activity of CAZ/AVI and other antibiotics against isolates of Gram-negative microorganisms found in patients with cUTI and cIAI in Colombian hospitals between 2014 and 2018, using the Antimicrobial Testing Leadership and Surveillance (ATLAS) database.⁸

We evaluated Enterobacterales and Pseudomonas aeruginosa obtained from patients with cUTI and cIAI in four hospitals in Colombia from 2014 to 2018.⁸ Each hospital selected different bacterial species regardless of their antimicrobial susceptibility. Abdominal fluid and urine samples were collected from adult, pediatric, and neonatal patients.⁹ Details for the identification, testing, detection of ESBL production, and identification of the genes have been previously described.¹⁰

During the period of 2014 and 2018, 565 Enterobacterales and 95 Pseudomonas aeruginosa were collected from patients with cUTI, and 345 Enterobacterales and 65 P. aeruginosa from patients with cIAI were isolated (Tables 1 and 2). More than 25% of Enterobacterales from cUTI patients were not susceptible to aztreonam (33.26%), cefepime (29.03%), and levofloxacin (36.46%), while non susceptibility to aztreonam (29.17%) and levofloxacin (28.41%) was observed in Enterobacterales from cIAI patients (Table 1). In vitro activity showed susceptibility to CAZ/AVI greater than 99% for Enterobacterales (Table 1) and in lower percentages for P. aeruginosa from cUTI patients (78.46%) and cIAI patients (83.33%) (Table 2). The proportion of CRE was 6.19% for isolates from cUTI patients and 11.59% for isolates from cIAI patients (Table 1).

Table 1
Antimicrobial activity among isolates of Enterobacterales, Carbapenem Resistant Enterobacterales, metallo b-lactamase negative producing, extended-spectrum b-lactamase, Klebsiella pneumoniae carbapenemase (KPC)-producing and multidrug-resistant enterobacterales in patients with cIAI or cUTI collected in Colombia between 2014 – 2018.

ntimicrobial	cUTI						cIAI				MBL negative n = 25
	Enterobacterales n = 565		CRE n = 31		MBL negative n = 31		Enterobacterales n = 345		CRE n = 35
	S	NS	S	NS	S	NS	S	NS	S	NS	S	NS
Amikacin	96.46	3.54	67.74	32.26	67.74	32.26	97.1	2.9	80	20	76	24
Aztreonam	66.74	33.26	0	100	0	100	70.83	29.17	0	100	0	100
Cefepime	70.97	29.03	6.45	93.55	6.45	93.55	77.39	22.61	2.86	97.14	4	96
CZA	99.58	0.42	96.15	3.85	96.15	3.85	99.58	0.42	95.65	4.35	95.65	4.35
Colistin	NA	100	NA	100	NA	100	NA	100	NA	100	NA	100
Levofloxacin	63.54	36.46	25.81	74.19	25.81	74.19	71.59	28.41	20	80	24	76
Meropenem	93.81	6.19	0	100	0	100	88.41	11.59	0	100	0	100
Pip/taz	82.83	17.17	0	100	0	100	76.23	23.77	0	100	0	100
Antimicrobial	cUTI						cIAI				MDRn = 107
	ESBL n = 21		KPC n = 40		MDR n = 194		ESBL n = 19		KPC n = 32
	S	NS	S	NS	S	NS	S	NS	S	NS	S	NS
Amikacin	100	0	72.5	27.5	91.24	8.76	100	0	81.25	18.75	91.59	8.41
Cefepime	61.9	38.1	25	75	16.57	73.71	52.63	47.37	18.75	81.25	36.45	63.55
Ceftazidime	33.33	66.67	22.5	77.5	26.29		36.84	63.16	15.63	84.37
CZA	100	0	100	0	98.9	1.1	100	0	96.67	3.33	98.84	1.16
Colistin	NA	100	NA	100	NA	100	NA	100	NA	100	NA	100
Levofloxacin	61.9	38.1	27.5	72.5	30.93	69.07	73.68	26.32	21.88	78.12	40.19	59.81
Meropenem	100	0	22.5	77.5	82.47	17.53	94.74	5.26	9.38	90.62	63.55	36.45
Pip/taz	38.1	61.9	5	95	62.37	37.63	47.37	52.63	0	100	29.91	70.09
Tigecycline	85.71	14.29	97.5	2.5			89.47	10.53	100	0

• Pip/taz, Piperacillin-tazobactam; CZA, Ceftazidime-Avibactam; cIAI, complicated intra-abdominal infection; cUTI, complicated Urinary Tract Infection; S, Susceptible; NS, Not susceptible; NA, No breakpoint available.

Table 2
Antimicrobial activity among isolates of P. aeruginosa, carbapenem resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing and multidrug-resistant Pseudomonas aeruginosa in patients with cIAI or cUTI collected in Colombia between 2014 – 2018.

	cUTI				cIAI
	P. aeruginosa n = 95		Carbapenem R n = 37		P. aeruginosa n = 65		Carbapenem R n = 20
Antimicrobial	S	NS	S	NS	S	NS	S	NS
Amikacin	76.84	23.16	40.54	59.46	78.46	21.54	35	65
Aztreonam	56.06	43.94	9.52	90.48	66.67	33.33	8.33	91.67
Cefepime	57.89	42.11	10.81	89.19	75.38	24.62	25	75
CZA	78.46	21.54	38.1	61.9	83.33	16.67	41.67	58.33
Colistin	NA	100	NA	100	NA	100	NA	100
Levofloxacin			16.22	83.78	63.08	36.92	5	95
Meropenem			0	100	58.46	41.54	0	100
Pip/taz	53.68	46.32	18.92	81.08	64.62	35.38	15	85
	cUTI				cIAI
	KPC n=8		MDR n = 35		KPC n=3		MDR n = 18
Antimicrobial	S	NS	S	NS	S	NS	S	NS
Amikacin	37.5	62.5	40	60	0	100	22.22	77.78
Aztreonam	0	100	4.35	95.65	0	100	9.09	90.91
Cefepime	0	100	0	100	0	100	11.11	88.89
CZA	50	50	43.48	56.52	33.33	66.67	27.27	72.73
Colistin	NA	100	NA	100	NA	100	NA	100
Levofloxacin	12.5	87.5	17.14	82.86	0	100	5.56	94.44
Meropenem	0	100	14.29	85.71	0	100	0	100
Pip/taz	0	100	5.71	94.29	0	100	11.11	88.89

• Pip/taz, Piperacillin-tazobactam; CZA, Ceftazidime-Avibactam; Carbapenem R, Carbapenem resistant; MDR, Multidrug-resistant; cIAI, complicated intra-abdominal infection; cUTI, complicated Urinary Tract Infection; S, Susceptible; NS, Not susceptible; NA, No breakpoint available.

CRE isolates from both cUTI and cIAI patients showed reduced susceptibility to most antibiotics. The antibiotic with best susceptibility profile for CRE was CAZ/AVI, with 96.15% of CRE isolates from cITU patients and 95.65% of CRE isolates from cIAI patients (Table 1). This in vitro activity was maintained in non-MBL-producing Enterobacterales, which showed susceptibility to CAZ/AVI of 96.15% for cUTI and 95.65% for cIAI (Table 1). The CAZ/AVI was the antibiotic with the best in vitro activity against ESBL-producing, KPC-producing, and MDR Enterobacterales in both types of infection (Table 1).

Regarding P. aeruginosa, CAZ/AVI was also the antibiotic with the best susceptibility profile, especially for isolates from cUTI patients (Table 2). For isolates from cIAI patients, P. aeruginosa with the highest susceptibility to CAZ/AVI was meropenem-resistant P. aeruginosa (41.67%), followed by KPC-producing P. aeruginosa (33.33%) (Table 2).

This study aimed to describe the in vitro susceptibility of Enterobacterales and P. aeruginosa to CAZ/AVI in patients with cUTI or cIAI. This antibiotic was found to present excellent in vitro activity, especially against Enterobacterales. In the case of P. aeruginosa, CAZ/AVI was the antibiotic that showed the best in vitro activity with susceptibility to it of less than 50%.

In several clinical trials, CAZ/AVI has shown noninferior efficacy for the treatment of cUTI and cIAI caused by MDR Gram-negative bacteria compared to the standard therapy.¹¹ Similar safety and risk of adverse events¹²,¹³ have also been observed in the use of CAZ/AVI. Even CAZ/AVI is cost-effective for the treatment of cUTI¹⁴ and management of carbapenem-resistant K. pneumoniae, having an impact on the number of deaths and patients’ quality of life.¹⁵ For this reason, CAZ/AVI has been approved in the United States of America, China, the European Union, and Colombia for the treatment of cUTI, cIAI, hospital-acquired pneumonia (including ventilator-associated pneumonia), and secondary bacteremia due to cUTI and cIAI.¹⁶

The CAZ/AVI showed excellent in vitro activity against CRE, MDR Enterobacterales, ESBL-producing, and KPC-producing Enterobacterales from patients with cUTI and cIAI, similar to other results reported in the scientific literature.⁴,⁵ The in vitro activity of CAZ/AVI against P. aeruginosa was lower than the in vitro activity against Enterobacterales, showing carbapenem-resistant, KPC-producing, and MDR Pseudomonas. This result could be due to the presence of class B or D enzymes in some P. aeruginosa strains, which decreases CAZ/AVI activity, as reported in other studies.⁵ This result could also be due to the increase of P. aeruginosa that carry bla_KPC-2, bla_KPC-3, and bla_VIM genes identified in Colombian hospitals.¹⁷ In this study, Enterobacterales were not susceptible to colistin because the CLSI in 2020 did not establish breakpoints for this category due to the limited clinical effectiveness of colistin when intermediate antimicrobial resistance is obtained.¹⁸

Some limitations of this study are related to the limited number of medical centers surveyed, the number of organisms tested, and the possible methodological variability, such as the participation of different hospitals, the years of the study, and the ways samples were collected and analyzed. There are clinical variables, such as the type of infection, antibiotic use, patients’ comorbidities, and the use of medical devices, that can modify the effectiveness of the antibiotic in clinical practice.

Conclusion

The CAZ/AVI is a therapeutic option to manage cUTI and cIAI caused by Enterobacterales. For P. aeruginosa, CAZ/AVI was the antibiotic that rated the best susceptibility, especially for cUTI.

• Funding
  ATLAS is funded by Pfizer. Medical writing support and publication fee were funded by Pfizer.

References

• ¹
  Osorio J, Barreto J, Samboni CF, Cándelo LA, Álvarez LC, Benavidez S, et al. Factores asociados a nefrotoxicidad por polimixina B en un hospital universitario de Neiva, Colombia. 2011-2015. Rev Chilena Infect. 2017;34:7-13.
• ²
  Castanheira M, Doyle TB, Deshpande LM, Mendes RE, Sader HS. Activity of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem-Relebactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals. Inter J Antimicrob Agen. 2021:106439.
• ³
  Gill CM, Aktaþ E, Alfouzan W, Bourassa L, Brink A, Burnham C-AD, et al. The ERACE-PA global surveillance program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro activity against a global collection of Carbapenem-resistant Pseudomonas aeruginosa. Euro J Clin Microbiol Infect Dis. 2021:1-9.
• ⁴
  Stone GG, Bradford PA, Yates K, Newell P. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections. J Antimicrob Chemother. 2017;72:1396-9.
• ⁵
  Stone GG, Bradford PA, Newell P, Wardman A. In Vitro activity of ceftazidime-avibactam against isolates in a phase 3 open-label clinical trial for complicated intra-abdominal and urinary tract infections caused by ceftazidime-nonsusceptible gram-negative pathogens. Antimicrob Agents Chemother. 2017;61. e01820-16.
• ⁶
  García-Castillo M, García-Fernández S, Gómez-Gil R, Pitart C, Oviaño M, Gracia-Ahufinger I, et al. Activity of ceftazidimeavibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain. Int J Antimicrob Agents. 2018;51:511-5.
• ⁷
  Ministerio de Salud y Proteccion Social, Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA. Resolucion No. 2019052727 de Noviembre 22 de 2019 [Internet]. 2019. Available from: https://www.invima.gov.co/documents/20143/1587207/INVIMA+2019M+19450-2019052727.pdf
  » https://www.invima.gov.co/documents/20143/1587207/INVIMA+2019M+19450-2019052727.pdf
• ⁸
  Pfizer. ATLAS (Antimicrobial Testing Leadership And Surveillance) [Internet]. Available from: https://atlas-surveillance.com//#/login
  » https://atlas-surveillance.com//#/login
• ⁹
  Scientific S, Unit HB. ATLAS : Fully - searchable global antibiotic resistance database to fight AMR Testing ATLAS : antimicrobial and surveillance history of Pfizer-sponsored surveillance progra ms. 2019.
• ¹⁰
  Lemos-Luengas EV, Rentería-Valoyes S, Cárdenas-Isaza P, Ramos-Castaneda JA. In vitro activity of ceftazidime/ avibactam against Gram-negative strains in Colombia 2014 -2018. J Global Antim Resist. 2022;29:141-6.
• ¹¹
  Vena A, Giacobbe DR, Castaldo N, Cattelan A, Mussini C, Luzzati R, et al. Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales. Antibiotics (Basel). 2020;9(2).
• ¹²
  Bradley JS, Broadhurst H, Cheng K, Mendez M, Newell P, Prchlik M, et al. Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children≥ 3 months to < 18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial. Pediatr Infect Dis J. 2019;38:816-24.
• ¹³
  Bradley JS, Roilides E, Broadhurst H, Cheng K, Huang L-M, MasCasullo V, et al. Safety and efficacy of Ceftazidime -Avibactam in the treatment of children≥ 3 months to < 18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial. Pediatr Infect Dis J. 2019;38:920-8.
• ¹⁴
  Kongnakorn T, Wagenlehner F, Falcone M, Tichy E, Di Virgilio R, Baillon-Plot N, et al. Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. Int J Antimicrob Agents. 2019;54(5):633-41.
• ¹⁵
  Varón-Vega F, Lemos E, Castaño GN, Reyes J. Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia. Expert Rev Pharmacoeconomics Outcomes Res. 2021;0:1-6.
• ¹⁶
  Dassner AM, Nicolau DP, Girotto JE. Management of pneumonia in the pediatric critical care unit: an area for antimicrobial stewardship. Curr Pediatr Rev. 2017;1:49-66.
• ¹⁷
  Bravo Ojeda JS. Descripcion de tipos de carbapenemasas expresadas en Klebsiella sp. y Pseudomonas aeruginosa en hospitales de tercer nivel de la ciudad de Bogota, estudio descriptivo. Parte 3: Comportamiento microbiologico y los mecanismos geneticos en aislamientos de Pseudomonas aeruginosa portadores del gen blaKPC en hospitales de tercer nivel de Bogota. 2020 Jul 1 [cited 2021 Nov 19]; Available from: https://repositorio.unal.edu.co/handle/unal/77807
  » https://repositorio.unal.edu.co/handle/unal/77807
• ¹⁸
  Clinical and Laboratory Standards Institute. M100 Performance Standards for Antimicrobial Susceptibility Testing. 30 ed. Wayne, PA: CLSI; 2020.

Publication Dates

• Publication in this collection
  15 July 2022
• Date of issue
  2022

History

• Received
  08 Jan 2022
• Accepted
  07 May 2022
• Published
  23 May 2022